ArriVent BioPharma (AVBP) SEC Filings: History & Chart

ArriVent BioPharma, Inc.(AVBP)

Biotechnology · Newtown Square, PA

$12.99-15.47 (-54.36%)

Delayed quote: Oct 6, 2026, 11:00 AM EDT

About ArriVent BioPharma, Inc.

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Newtown Square, PA

77 employees

arrivent.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Zhengbin Yao

View full financials

Form	Filing Date	Accepted	Document
10-Q	Aug 12, 2026	Aug 12, 2026	View filing
8-K	Aug 12, 2026	Aug 12, 2026	View filing
SC 13G/A	Jul 27, 2026	Jul 27, 2026	View filing
4	Jun 22, 2026	Jun 22, 2026	View filing
4	Jun 22, 2026	Jun 22, 2026	View filing
4	Jun 22, 2026	Jun 22, 2026	View filing
4	Jun 22, 2026	Jun 22, 2026	View filing
8-K	Jun 22, 2026	Jun 22, 2026	View filing
8-K	May 11, 2026	May 11, 2026	View filing
424B5	May 11, 2026	May 11, 2026	View filing
10-Q	May 11, 2026	May 11, 2026	View filing
8-K	May 11, 2026	May 11, 2026	View filing
SC 13G/A	May 6, 2026	May 6, 2026	View filing
ARS	Apr 28, 2026	Apr 28, 2026	View filing
DEFA14A	Apr 28, 2026	Apr 28, 2026	View filing
DEF 14A	Apr 28, 2026	Apr 28, 2026	View filing
8-K	Mar 17, 2026	Mar 17, 2026	View filing
S-8	Mar 5, 2026	Mar 5, 2026	View filing
10-K	Mar 5, 2026	Mar 5, 2026	View filing
8-K	Mar 5, 2026	Mar 5, 2026	View filing
SC 13G/A	Mar 5, 2026	Mar 5, 2026	View filing
SC 13G/A	Feb 17, 2026	Feb 17, 2026	View filing
SC 13G/A	Feb 17, 2026	Feb 17, 2026	View filing
4	Feb 4, 2026	Feb 4, 2026	View filing
4	Feb 4, 2026	Feb 4, 2026	View filing
4	Feb 4, 2026	Feb 4, 2026	View filing
4	Feb 4, 2026	Feb 4, 2026	View filing
4	Feb 4, 2026	Feb 4, 2026	View filing
4	Feb 3, 2026	Feb 3, 2026	View filing
SC 13G/A	Jan 30, 2026	Jan 30, 2026	View filing

SEC Filings

Recent Filings